Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.14 Insider Own22.84% Shs Outstand36.83M Perf Week34.85%
Market Cap142.90M Forward P/E- EPS next Y-0.80 Insider Trans84.34% Shs Float30.97M Perf Month36.92%
Income-58.21M PEG- EPS next Q-0.31 Inst Own67.62% Short Float1.02% Perf Quarter117.07%
Sales0.00M P/S- EPS this Y-16.55% Inst Trans-0.33% Short Ratio0.59 Perf Half Y363.96%
Book/sh1.77 P/B2.02 EPS next Y32.40% ROA-52.46% Short Interest0.31M Perf Year60.36%
Cash/sh1.99 P/C1.79 EPS next 5Y- ROE-58.75% 52W Range0.72 - 3.72 Perf YTD258.69%
Dividend Est.- P/FCF- EPS past 5Y48.08% ROI-80.09% 52W High-4.30% Beta1.23
Dividend TTM- Quick Ratio11.82 Sales past 5Y0.00% Gross Margin- 52W Low394.44% ATR (14)0.38
Dividend Ex-Date- Current Ratio11.82 EPS Y/Y TTM-6.90% Oper. Margin0.00% RSI (14)65.31 Volatility21.38% 12.65%
Employees51 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq0.03 EPS Q/Q-10.10% Payout- Rel Volume1.69 Prev Close3.06
Sales Surprise- EPS Surprise-12.81% Sales Q/Q- EarningsMay 15 AMC Avg Volume533.12K Price3.56
SMA2025.00% SMA5035.12% SMA200131.52% Trades Volume900,849 Change16.34%
Date Action Analyst Rating Change Price Target Change
Apr-09-24Initiated Maxim Group Buy $8
Aug-02-22Resumed Canaccord Genuity Buy $17
Jun-15-22Initiated Cantor Fitzgerald Overweight $9
Sep-08-21Initiated ROTH Capital Buy $21
May-27-21Initiated Oppenheimer Outperform $25
May-25-21Initiated H.C. Wainwright Buy $21
May-22-24 07:23AM
May-21-24 04:05PM
May-15-24 10:54PM
08:00AM Loading…
Apr-23-24 08:00AM
Mar-20-24 02:33PM
Mar-06-24 07:30AM
Feb-13-24 04:05PM
Jan-24-24 08:00AM
Jan-23-24 08:00AM
Dec-14-23 08:00AM
Dec-13-23 08:00AM
Nov-24-23 11:14AM
Nov-17-23 08:00AM
04:05PM Loading…
Nov-13-23 04:05PM
Oct-17-23 08:00AM
Oct-11-23 08:00AM
Sep-14-23 04:05PM
Sep-06-23 07:00AM
Jun-27-23 04:05PM
Jun-01-23 12:45PM
May-11-23 04:05PM
Mar-23-23 04:50PM
Mar-08-23 07:00AM
Feb-10-23 04:05PM
Dec-15-22 07:00AM
Nov-09-22 04:05PM
Nov-01-22 07:00AM
Oct-20-22 07:00AM
04:05PM Loading…
Sep-15-22 04:05PM
Sep-07-22 07:00AM
Aug-15-22 08:36AM
Jun-01-22 07:00AM
May-12-22 04:05PM
May-04-22 04:01PM
May-01-22 11:25PM
Apr-26-22 04:05PM
Mar-29-22 07:00AM
Mar-23-22 07:00AM
Feb-22-22 07:00AM
Feb-09-22 04:05PM
Nov-12-21 04:05PM
Oct-19-21 12:14PM
Oct-13-21 08:10AM
Oct-12-21 04:05PM
Sep-22-21 04:05PM
Sep-15-21 04:56PM
Sep-09-21 04:05PM
Sep-07-21 04:05PM
Aug-10-21 07:00AM
Aug-03-21 07:00AM
Jun-28-21 07:00AM
Jun-24-21 09:01PM
Jun-03-21 05:35AM
May-31-21 10:17AM
May-27-21 07:00AM
May-20-21 07:00AM
May-18-21 07:00AM
May-17-21 04:05PM
May-04-21 08:00AM
Apr-19-21 08:00AM
Mar-22-21 08:00AM
Mar-08-21 08:00AM
Mar-02-21 05:16PM
Feb-10-21 04:05PM
Jan-12-21 08:30AM
Jan-11-21 07:56AM
Dec-28-20 04:05PM
Dec-03-20 08:00AM
Nov-19-20 08:00AM
Nov-05-20 08:00AM
Oct-09-20 08:30AM
Sep-10-20 08:00AM
Jul-27-20 08:00AM
Jun-15-20 08:30AM
May-28-20 08:30AM
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBERTS BRIAN KENNETHChief Medical OfficerMar 28 '24Buy2.555001,2751,076Mar 29 11:08 AM
Evans DaronCFOMar 15 '24Buy1.6920,00033,83020,000Mar 19 09:17 AM
ROBERTS BRIAN KENNETHChief Medical OfficerMar 14 '24Buy1.8810,00018,80010,000Mar 18 11:20 AM
Evans DaronCFOMar 08 '24Buy1.9350,00096,345120,900Mar 08 12:37 PM
Kim Young-JinDirectorMar 07 '24Buy1.9136,50369,859115,450Mar 14 10:35 AM
ROBERTS BRIAN KENNETHChief Medical OfficerMar 07 '24Buy1.85500925500Mar 11 10:35 AM
Elam Nevan CCEOFeb 26 '24Buy1.685,0008,4007,817Feb 28 11:40 AM
ROBERTS BRIAN KENNETHChief Medical OfficerFeb 26 '24Buy1.702,0003,40042,552Feb 27 08:47 AM
ROBERTS BRIAN KENNETHChief Medical OfficerFeb 23 '24Buy1.696,00010,14040,552Feb 27 08:47 AM
Evans DaronCFOFeb 16 '24Buy1.3041,90054,41170,900Feb 20 07:01 AM
Evans DaronCFOFeb 16 '24Buy1.379,00012,3304,500Feb 20 07:01 AM
ROBERTS BRIAN KENNETHChief Medical OfficerFeb 16 '24Buy1.317,0009,14234,552Feb 21 11:55 AM
ROBERTS BRIAN KENNETHChief Medical OfficerJul 03 '23Buy1.905,0009,50027,552Jul 06 11:18 AM